BR0105457A - Combinações terapêuticas para estimulação do crescimento ósseo - Google Patents
Combinações terapêuticas para estimulação do crescimento ósseoInfo
- Publication number
- BR0105457A BR0105457A BR0105457-0A BR0105457A BR0105457A BR 0105457 A BR0105457 A BR 0105457A BR 0105457 A BR0105457 A BR 0105457A BR 0105457 A BR0105457 A BR 0105457A
- Authority
- BR
- Brazil
- Prior art keywords
- combinations
- bone growth
- stimulate bone
- therapeutic combinations
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMBINAçõES TERAPêUTICAS PARA ESTIMULAçãO DO CRESCIMENTO óSSEO". Esta invenção refere-se às combinações farmacêuticas de um agonista de prostaglandinas e um inibidor da HMG-CoA redutase, métodos de utilização destas combinações e kits contendo estas combinações. As combinações farmacêuticas, métodos e kits são úteis para intensificar a formação óssea em mamíferos, incluindo seres humanos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24645300P | 2000-11-07 | 2000-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0105457A true BR0105457A (pt) | 2002-06-25 |
Family
ID=22930749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0105457-0A BR0105457A (pt) | 2000-11-07 | 2001-11-07 | Combinações terapêuticas para estimulação do crescimento ósseo |
Country Status (6)
Country | Link |
---|---|
US (3) | US20020161026A1 (pt) |
EP (1) | EP1205189A3 (pt) |
JP (1) | JP2002179595A (pt) |
BR (1) | BR0105457A (pt) |
CA (1) | CA2361071A1 (pt) |
MX (1) | MXPA01011302A (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004019884A2 (en) * | 2002-08-29 | 2004-03-11 | Regents Of The University Of California, The | Agents and methods for enhancing bone formation |
ES2393321T3 (es) | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
JP2006526640A (ja) * | 2003-05-30 | 2006-11-24 | コンビナトアールエックス インコーポレーティッド | 新生物を治療するための併用治療 |
EP2422814A1 (en) * | 2003-07-25 | 2012-02-29 | Ono Pharmaceutical Co., Ltd. | Remedy for cartilage-related diseases |
US9532994B2 (en) * | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
WO2006114073A1 (de) * | 2005-04-23 | 2006-11-02 | Ixetic Mac Gmbh | Axialkolbenmaschine |
US7696235B2 (en) * | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
AU2006284650A1 (en) * | 2005-09-02 | 2007-03-08 | The Regents Of The University Of California | Osteogenic and anti-adipogenic oxysterols |
EP1993558B1 (en) * | 2006-02-27 | 2014-07-30 | The Regents of The University of California | Oxysterol compounds and the hedgehog pathway |
EP2005342B1 (en) * | 2006-04-08 | 2019-06-05 | Allan Millman | Method and system for interactive simulation of materials |
US8786613B2 (en) | 2006-04-08 | 2014-07-22 | Alan Millman | Method and system for interactive simulation of materials and models |
WO2008011071A2 (en) * | 2006-07-19 | 2008-01-24 | The Regents Of The University Of California | Interactions of hedgehog and liver x receptor signaling pathways |
EP2059507B1 (en) * | 2006-07-28 | 2013-03-20 | Pfizer Products Inc. | Ep2 agonist |
CA2673513A1 (en) | 2006-12-19 | 2008-07-10 | The Regents Of University Of California | Inhibition of ppar gamma expression by specific osteogenic oxysterols |
EP2146724A2 (en) * | 2007-03-16 | 2010-01-27 | The Regent of the University of California | Role of hedgehog signaling in atherosclerosis and cardiovascular disease |
CA2707663C (en) * | 2007-12-03 | 2017-05-30 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
US20090183503A1 (en) * | 2008-01-18 | 2009-07-23 | Alberto Verdesi | Exhaust apparatus |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
JP6262723B2 (ja) | 2012-05-07 | 2018-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | オキシステロールアナログoxy133は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する |
WO2014069401A1 (ja) | 2012-10-29 | 2014-05-08 | 株式会社カルディオ | 肺疾患特異的治療剤 |
CA2911205A1 (en) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3932389A (en) * | 1974-12-11 | 1976-01-13 | Pfizer Inc. | 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins |
US4018892A (en) * | 1975-08-06 | 1977-04-19 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US3982016A (en) * | 1975-08-06 | 1976-09-21 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4000309A (en) * | 1975-08-06 | 1976-12-28 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4132847A (en) * | 1977-07-22 | 1979-01-02 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
US4097601A (en) * | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
US4219483A (en) * | 1978-09-11 | 1980-08-26 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
US5216183A (en) * | 1988-04-19 | 1993-06-01 | Teijin Limited | Cyclopentanone/cyclopentenone derivative |
GB8813339D0 (en) * | 1988-06-06 | 1988-07-13 | Sandoz Ltd | Improvements in/relating to organic compounds |
US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
JP3865786B2 (ja) * | 1996-12-17 | 2007-01-10 | ゾルファイ フルーオル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1,1,1,3,3−ペンタフルオロブタンを含有する混合物 |
AU4682700A (en) * | 1999-04-30 | 2000-11-17 | Research Corporation Technologies, Inc. | Bone targeting agents for osteoporosis |
-
2001
- 2001-10-29 US US10/101,120 patent/US20020161026A1/en active Pending
- 2001-10-29 US US10/020,295 patent/US20020115695A1/en not_active Abandoned
- 2001-11-05 CA CA002361071A patent/CA2361071A1/en not_active Abandoned
- 2001-11-06 JP JP2001340488A patent/JP2002179595A/ja active Pending
- 2001-11-06 MX MXPA01011302A patent/MXPA01011302A/es unknown
- 2001-11-06 EP EP01309413A patent/EP1205189A3/en not_active Withdrawn
- 2001-11-07 BR BR0105457-0A patent/BR0105457A/pt not_active IP Right Cessation
-
2004
- 2004-03-16 US US10/801,827 patent/US20040176423A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020161026A1 (en) | 2002-10-31 |
US20020115695A1 (en) | 2002-08-22 |
EP1205189A2 (en) | 2002-05-15 |
US20040176423A1 (en) | 2004-09-09 |
CA2361071A1 (en) | 2002-05-07 |
JP2002179595A (ja) | 2002-06-26 |
EP1205189A3 (en) | 2002-12-04 |
MXPA01011302A (es) | 2002-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0105457A (pt) | Combinações terapêuticas para estimulação do crescimento ósseo | |
ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
RS50091B (sr) | Upotreba retigabina u lečenju neuropatskog bola | |
EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
BR0212809A (pt) | Inibidores de anticorpos de gdf-8 e usos dos mesmos | |
DE60223254D1 (de) | Verzögert freisetzende formulierungen von oxymorphon | |
ES2191152T3 (es) | Terapia combinada para el tratamiento de psicosis. | |
AR005987A1 (es) | Terapia combinada para la osteoporosis | |
CY1111386T1 (el) | Ενωσεις και μεθοδοι για αυξηση νευρογενεσης | |
CR9465A (es) | Compuestos mejorados farmacocineticamente | |
PT1305286E (pt) | Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento | |
PA8452701A1 (es) | Agonistas de prostaglandinas | |
DE60313004D1 (de) | Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination | |
DE60013098D1 (de) | Zusammensetzung zur hautdesinfizierung | |
PT1325011E (pt) | Metodos e compostos para tratamento de doencas proliferativas | |
BR0002953A (pt) | Composições e tratamento para complicações diabéticas | |
BR0114379A (pt) | Derivados de c-ciclohexilmetilamina substituìdos | |
DE69835288D1 (de) | Kombinationstherapie zur modulation der humanen sexualreaktion | |
DE60129032D1 (de) | Creatinester-pronutrient-verbindungen und formulierungen | |
BR0206844A (pt) | Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |